These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23735831)

  • 1. Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.
    Welker ME; Kulik G
    Bioorg Med Chem; 2013 Jul; 21(14):4063-91. PubMed ID: 23735831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.
    Falasca M; Chiozzotto D; Godage HY; Mazzoletti M; Riley AM; Previdi S; Potter BV; Broggini M; Maffucci T
    Br J Cancer; 2010 Jan; 102(1):104-14. PubMed ID: 20051961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
    Chiarini F; Falà F; Tazzari PL; Ricci F; Astolfi A; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2009 Apr; 69(8):3520-8. PubMed ID: 19351820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.
    Dienstmann R; Rodon J; Serra V; Tabernero J
    Mol Cancer Ther; 2014 May; 13(5):1021-31. PubMed ID: 24748656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
    Feldman ME; Shokat KM
    Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
    Singh P; Kumar V; Gupta SK; Kumari G; Verma M
    Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PI3-kinase/Akt/mTOR signaling pathway.
    Hassan B; Akcakanat A; Holder AM; Meric-Bernstam F
    Surg Oncol Clin N Am; 2013 Oct; 22(4):641-64. PubMed ID: 24012393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.
    Fiskus W; Verstovsek S; Manshouri T; Smith JE; Peth K; Abhyankar S; McGuirk J; Bhalla KN
    Mol Cancer Ther; 2013 May; 12(5):577-88. PubMed ID: 23445613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
    Wu X; Yu J; Yan J; Dai J; Si L; Chi Z; Sheng X; Cui C; Ma M; Tang H; Xu T; Yu H; Kong Y; Guo J
    Cancer Biol Ther; 2018 Jul; 19(7):584-589. PubMed ID: 29708815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
    Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
    Ewald F; Nörz D; Grottke A; Hofmann BT; Nashan B; Jücker M
    Invest New Drugs; 2014 Dec; 32(6):1144-54. PubMed ID: 25152244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
    Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
    PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
    Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS
    Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
    Wu P; Hu YZ
    Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K inhibitors protect against glucocorticoid-induced skin atrophy.
    Agarwal S; Mirzoeva S; Readhead B; Dudley JT; Budunova I
    EBioMedicine; 2019 Mar; 41():526-537. PubMed ID: 30737086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia.
    Sacco A; Roccaro A; Ghobrial IM
    Oncotarget; 2010 Nov; 1(7):578-582. PubMed ID: 21317453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
    Bressanin D; Evangelisti C; Ricci F; Tabellini G; Chiarini F; Tazzari PL; Melchionda F; Buontempo F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
    Oncotarget; 2012 Aug; 3(8):811-23. PubMed ID: 22885370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
    Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
    Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.